IP Verse

Methods Of Treating Pancreatic Cancer - EP2943192

The patent EP2943192 was granted to Abraxis Bioscience on Sep 29, 2021. The application was originally filed on Jan 10, 2014 under application number EP14737791A. The patent is currently recorded with a legal status of "Revoked".

EP2943192

ABRAXIS BIOSCIENCE
Application Number
EP14737791A
Filing Date
Jan 10, 2014
Status
Revoked
Jun 17, 2022
Publication Date
Sep 29, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREFeb 11, 2022TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSFeb 10, 2022D YOUNGADMISSIBLE
GENERICS UKJan 17, 2022ELKINGTON AND FIFEADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2006263434
DESCRIPTIONUS2007082838
DESCRIPTIONUS2013005678
DESCRIPTIONUS5916596
DESCRIPTIONUS6096331
DESCRIPTIONUS6506405
DESCRIPTIONUS6537579
DESCRIPTIONUS6749868
DESCRIPTIONUS7820788
DESCRIPTIONWO2008137148
DESCRIPTIONWO2011153010
INTERNATIONAL-SEARCH-REPORTWO2011123393
OPPOSITIONUS2006263434
OPPOSITIONWO2011153010
OPPOSITIONWO2014110443
SEARCHWO2011153010

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Fda, "ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20130901), pages 1 - 24, HIGHLIGHTS OF PRESCRIBING INFORMATION, (20220228), XP055895983
OPPOSITION- FDA, "ABRAXANE® for Injectable Suspension (paclitaxel protein-boundparticles for injectable suspension) (albumin-bound)", Highlights of Prescribing Information (FDA), (20121000), URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021660s031lbl.pdf, XP055895862
OPPOSITION- Nikitas Papadoniou, Christos Kosmas, Kostadinos Gennatas, Aris Polyzos, Despina Mouratidou, Elias Skopelitis, Michalis Tzivras, Stavros Sougioultzis, George Papastratis, Gavrilos Karatzas, Efstathios Papalambros, Nikolas Tsavaris, "Prognostic Factors in Patients with Locally Advanced (Unresectable) or Metastatic Pancreatic Adenocarcinoma: A Retrospective Analysis", Anticancer Research, (20080101), vol. 28, pages 543 - 550, XP055895857
OPPOSITION- Dong-Sheng Zhang, Wang De-Shen, Wang Zhi-Qiang, Wang Feng-Hua, Luo Hui-Yan, Qiu Miao-Zhen, Wang Feng, Li Yu-Hong, Xu Rui-Hua, "Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer", Cancer Chemotherapy and Pharmacology, Springer., (20130401), vol. 71, no. 4, doi:10.1007/s00280-013-2102-4, ISSN 03445704, pages 1065 - 1072, XP055142768
OPPOSITION- Zhang Dong-sheng; Wang De-shen; Wang Zhi-qiang; Wang Feng-hua; Luo Hui-yan; Qiu Miao-zhen; Wang Feng; Li Yu-hong; Xu Rui-hua, "Phase I/II study of albumin-boundnab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer", Cancer chemotherapy and pharmacology, Springer Verlag , Berlin, DE, DE , (20130313), vol. 71, no. 4, doi:10.1007/s00280-013-2102-4, ISSN 0344-5704, pages 1065 - 1072, XP035339858
OPPOSITION- Yasuhiro Murata; Takashi Hamada; Masashi Kishiwada; Ichiro Ohsawa; Shugo Mizuno; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Noriko Ii; Hiroyuki Inoue; Taizo Shiraishi; Shuji Isaji, "Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy", Journal of Hepato-Biliary-Pancreatic Sciences ; (formerly: Journal of Hepato-Biliary-Pancreatic Surgery), Springer Japan, Japan, Japan , (20110907), vol. 19, no. 4, doi:10.1007/s00534-011-0440-3, ISSN 1868-6982, pages 413 - 425, XP035086569
OPPOSITION- Umashankar K. Ballehaninna, Ronald S. Chamberlain, "Serum CA 19-9 as a Biomarker for Pancreatic Cancer— A Comprehensive Review", Indian Journal of Surgical Oncology, Springer India, India, India , (20110601), vol. 2, no. 2, doi:10.1007/s13193-011-0042-1, ISSN 0975-7651, pages 88 - 100, XP055347673
OPPOSITION- Umashankar K. Ballehaninna, Ronald S. Chamberlain, "Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review", Indian Journal of Surgical Oncology, Springer India, India, India , (20110601), vol. 2, no. 2, doi:10.1007/s13193-011-0042-1, ISSN 0975-7651, pages 88 - 100, XP055347673
OPPOSITION- Daniel D. Von Hoff, Thomas Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A. Tjulandin, Wen Wee Ma, Mansoor N. Saleh, Marion Harris, Michele Reni, Scot Dowden, Daniel Laheru, Nathan Bahary, Ramesh K. Ramanathan, Josep Tabernero, Manuel Hidalgo, David Goldstein, Eric Van Cutsem, Xinyu Wei, Jose Iglesias, Markus F. Renschler, "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine", The New England journal of medicine, Massachusetts Medical Society, US, US , (20131031), vol. 369, no. 18, doi:10.1056/NEJMoa1304369, ISSN 0028-4793, pages 1691 - 1703, XP055250743
OPPOSITION- Artinyan Avo, Soriano Perry A., Prendergast Christina, Low Tracey, Ellenhorn Joshua D.I., Kim Joseph, "The anatomic location of pancreatic cancer is a prognostic factor for survival", HPB, ISIS MEDICAL MEDIA, OXFORD, GB, GB , (20081001), vol. 10, no. 5, doi:10.1080/13651820802291233, ISSN 1365-182X, pages 371 - 376, XP055887894
OPPOSITION- D. D. Von Hoff, Ramanathan Ramesh K, Borad Mitesh J, Laheru Daniel A, Smith Lon S, Wood Tina E, Korn Ronald L, Desai Neil, Trieu Vuong, Iglesias Jose L, Zhang Hui, Soon-Shiong Patrick, Shi Tao, Rajeshkumar N V, Maitra Anirban, Hidalgo Manuel, Ramana-Than Ramesh K, Virginia Tgen /, Piper G, Center Cancer, Mitesh ;, Borad J, Clinic Mayo, Ronald L, Rajeshku-Mar N V, The Sol, Goldman, Antonio San, Tx, Al, Igle-Sias Jose L, "Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20111201), vol. 29, no. 34, doi:10.1200/JCO.2011.36.5742, ISSN 0732-183X, pages 4548 - 4554, XP055243146
OPPOSITION- VON HOFF et al., "Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in D2 Patients With Advanced Pancreatic Cancer: A Phase 1/11 Trial", Journal of Clinical Oncology, (20110000), vol. 29, no. 34, doi:10.1200/JCO.2011.36.5742, pages 4548 - 4554, XP055243146
SEARCH- DONG-SHENG ZHANG ET AL, "Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer", CANCER CHEMOTHERAPY AND PHARMACOLOGY, (20130313), vol. 71, no. 4, doi:10.1007/s00280-013-2102-4, ISSN 0344-5704, pages 1065 - 1072, XP055142768 [XP] 1-15 * discussion *
SEARCH- YASUHIRO MURATA ET AL, "Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy", JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES ; (FORMERLY: JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY), SPRINGER JAPAN, JAPAN, (20110907), vol. 19, no. 4, doi:10.1007/S00534-011-0440-3, ISSN 1868-6982, pages 413 - 425, XP035086569 [A] 1-15 * discussion *
SEARCH- DANIEL D. VON HOFF ET AL, "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine", NEW ENGLAND JOURNAL OF MEDICINE, US, (20131031), vol. 369, no. 18, doi:10.1056/NEJMoa1304369, ISSN 0028-4793, pages 1691 - 1703, XP055250743 [XP] 1-15 * table - *
SEARCH- D. D. VON HOFF ET AL, "Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial", JOURNAL OF CLINICAL ONCOLOGY, US, (20111201), vol. 29, no. 34, doi:10.1200/JCO.2011.36.5742, ISSN 0732-183X, pages 4548 - 4554, XP055243146 [X] 1-3,5-15 * the whole article;; table 1 * [I] 1-15

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents